CereVasc

CereVasc, Inc. is a clinical-stage medical device company located in Massachusetts. The company focuses on developing innovative, minimally invasive treatments for neurological diseases, particularly communicating hydrocephalus (CH). Its flagship product, the eShunt System, is a patented, endovascularly implantable cerebral spinal fluid shunt designed to treat CH without the need for invasive surgery. The eShunt System offers a unique approach by enabling percutaneous transvenous-transdural access to the central nervous system, making it the first minimally invasive treatment option for this condition. This device aims to enhance patient outcomes while reducing the costs and risks associated with traditional surgical methods. Developed with input from leading neurosurgeons, the eShunt System is designed for less invasive implantation through the vascular system. CereVasc has secured significant funding, including a $70 million Series B financing round, to support clinical trials and regulatory approvals for the eShunt System. The company has also received FDA Breakthrough Device Designation, highlighting its commitment to advancing treatment options for patients with communicating hydrocephalus.

• Employees 34
• Founded 2013
• Total Funding $114000000